TY - JOUR
T1 - The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations
AU - Ten Haaf, Kevin
AU - de Nijs, Koen
AU - Simoni, Giulia
AU - Alban, Andres
AU - Cao, Pianpian
AU - Sun, Zhuolu
AU - Yong, Jean
AU - Jeon, Jihyoun
AU - Toumazis, Iakovos
AU - Han, Summer S
AU - Gazelle, G Scott
AU - Kong, Chung Ying
AU - Plevritis, Sylvia K
AU - Meza, Rafael
AU - de Koning, Harry J
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7
Y1 - 2024/7
N2 - Background: Recommendations regarding personalized lung cancer screening are being informed by natural-history modeling. Therefore, understanding how differences in model assumptions affect model-based personalized screening recommendations is essential. Design: Five Cancer Intervention and Surveillance Modeling Network (CISNET) models were evaluated. Lung cancer incidence, mortality, and stage distributions were compared across 4 theoretical scenarios to assess model assumptions regarding 1) sojourn times, 2) stage-specific sensitivities, and 3) screening-induced lung cancer mortality reductions. Analyses were stratified by sex and smoking behavior. Results: Most cancers had sojourn times <5 y (model range [MR]; lowest to highest value across models: 83.5%–98.7% of cancers). However, cancer aggressiveness still varied across models, as demonstrated by differences in proportions of cancers with sojourn times <2 y (MR: 42.5%–64.6%) and 2 to 4 y (MR: 28.8%–43.6%). Stage-specific sensitivity varied, particularly for stage I (MR: 31.3%–91.5%). Screening reduced stage IV incidence in most models for 1 y postscreening; increased sensitivity prolonged this period to 2 to 5 y. Screening-induced lung cancer mortality reductions among lung cancers detected at screening ranged widely (MR: 14.6%–48.9%), demonstrating variations in modeled treatment effectiveness of screen-detected cases. All models assumed longer sojourn times and greater screening-induced lung cancer mortality reductions for women. Models assuming differences in cancer epidemiology by smoking behaviors assumed shorter sojourn times and lower screening-induced lung cancer mortality reductions for heavy smokers. Conclusions: Model-based personalized screening recommendations are primarily driven by assumptions regarding sojourn times (favoring longer intervals for groups more likely to develop less aggressive cancers), sensitivity (higher sensitivities favoring longer intervals), and screening-induced mortality reductions (greater reductions favoring shorter intervals). Implications: Models suggest longer screening intervals may be feasible and benefits may be greater for women and light smokers. Natural-history models are increasingly used to inform lung cancer screening, but causes for variations between models are difficult to assess. This is the first evaluation of these causes and their impact on personalized screening recommendations through easily interpretable metrics. Models vary regarding sojourn times, stage-specific sensitivities, and screening-induced lung cancer mortality reductions. Model outcomes were similar in predicting greater screening benefits for women and potentially light smokers. Longer screening intervals may be feasible for women and light smokers.
AB - Background: Recommendations regarding personalized lung cancer screening are being informed by natural-history modeling. Therefore, understanding how differences in model assumptions affect model-based personalized screening recommendations is essential. Design: Five Cancer Intervention and Surveillance Modeling Network (CISNET) models were evaluated. Lung cancer incidence, mortality, and stage distributions were compared across 4 theoretical scenarios to assess model assumptions regarding 1) sojourn times, 2) stage-specific sensitivities, and 3) screening-induced lung cancer mortality reductions. Analyses were stratified by sex and smoking behavior. Results: Most cancers had sojourn times <5 y (model range [MR]; lowest to highest value across models: 83.5%–98.7% of cancers). However, cancer aggressiveness still varied across models, as demonstrated by differences in proportions of cancers with sojourn times <2 y (MR: 42.5%–64.6%) and 2 to 4 y (MR: 28.8%–43.6%). Stage-specific sensitivity varied, particularly for stage I (MR: 31.3%–91.5%). Screening reduced stage IV incidence in most models for 1 y postscreening; increased sensitivity prolonged this period to 2 to 5 y. Screening-induced lung cancer mortality reductions among lung cancers detected at screening ranged widely (MR: 14.6%–48.9%), demonstrating variations in modeled treatment effectiveness of screen-detected cases. All models assumed longer sojourn times and greater screening-induced lung cancer mortality reductions for women. Models assuming differences in cancer epidemiology by smoking behaviors assumed shorter sojourn times and lower screening-induced lung cancer mortality reductions for heavy smokers. Conclusions: Model-based personalized screening recommendations are primarily driven by assumptions regarding sojourn times (favoring longer intervals for groups more likely to develop less aggressive cancers), sensitivity (higher sensitivities favoring longer intervals), and screening-induced mortality reductions (greater reductions favoring shorter intervals). Implications: Models suggest longer screening intervals may be feasible and benefits may be greater for women and light smokers. Natural-history models are increasingly used to inform lung cancer screening, but causes for variations between models are difficult to assess. This is the first evaluation of these causes and their impact on personalized screening recommendations through easily interpretable metrics. Models vary regarding sojourn times, stage-specific sensitivities, and screening-induced lung cancer mortality reductions. Model outcomes were similar in predicting greater screening benefits for women and potentially light smokers. Longer screening intervals may be feasible for women and light smokers.
UR - http://www.scopus.com/inward/record.url?scp=85199812739&partnerID=8YFLogxK
U2 - 10.1177/0272989X241249182
DO - 10.1177/0272989X241249182
M3 - Article
C2 - 38738534
SN - 0272-989X
VL - 44
SP - 497
EP - 511
JO - Medical Decision Making
JF - Medical Decision Making
IS - 5
ER -